Shares of OPKO Health OPK rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 266.67% over the past year to $0.05, which beat the estimate of $0.04.
Revenue of $494,600,000 rose by 120.51% from the same period last year, which beat the estimate of $443,100,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Feb 18, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/6zz49oxj
Recent Stock Performance
Company's 52-week high was at $6.47
Company's 52-week low was at $1.12
Price action over last quarter: Up 53.41%
Company Description
Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
